Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Intangibles (2020 - 2025)

Historic Intangibles for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $377.4 million.

  • Bioventus' Intangibles fell 901.88% to $377.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $377.4 million, marking a year-over-year decrease of 901.88%. This contributed to the annual value of $404.7 million for FY2024, which is 1609.23% down from last year.
  • Bioventus' Intangibles amounted to $377.4 million in Q3 2025, which was down 901.88% from $387.0 million recorded in Q2 2025.
  • Over the past 5 years, Bioventus' Intangibles peaked at $1.1 billion during Q4 2022, and registered a low of $248.8 million during Q4 2021.
  • In the last 5 years, Bioventus' Intangibles had a median value of $470.7 million in 2024 and averaged $494.1 million.
  • Its Intangibles has fluctuated over the past 5 years, first surged by 32428.72% in 2022, then plummeted by 5326.61% in 2023.
  • Quarter analysis of 5 years shows Bioventus' Intangibles stood at $695.2 million in 2021, then fell by 7.96% to $639.9 million in 2022, then dropped by 24.62% to $482.4 million in 2023, then decreased by 16.09% to $404.7 million in 2024, then fell by 6.75% to $377.4 million in 2025.
  • Its Intangibles stands at $377.4 million for Q3 2025, versus $387.0 million for Q2 2025 and $395.7 million for Q1 2025.